Veloxity Labs is an employee-owned bioanalytical CRO founded to challenge traditional timelines without compromising scientific rigor or data quality. Our team brings decades of experience, a culture of urgency and an operating model designed for responsive study execution.
Veloxity Labs supports pharmaceutical, biotech and animal health programs across discovery, preclinical and clinical development with LC-MS/MS bioanalysis, method
development, PK/TK support and quality-focused study execution. Our scientists work across small molecules, peptides, proteins, ADCs and other complex therapeutics, with additional expertise in microsampling and patient-centric sampling approaches.
Founded to address the delays that can slow bioanalytical programs, Veloxity combines experienced scientists, responsive collaboration and an operating model designed to maintain capacity for rapid study initiation. As an employee-owned company, our team has a direct stake in the quality of the work and the experience we deliver to clients.
Veloxity’s leadership team brings experience across bioanalysis, drug development, quality, laboratory operations, business development and scientific instrumentation.
Co-Founder, President & CEO
With more than 30 years of experience in bioanalysis and more than 200 publications, Shane is a recognized scientist, entrepreneur and industry leader. He has founded multiple businesses and CROs and has helped advance approaches in dried blood spot analysis, microflow LC-MS/MS and small- and large-molecule bioanalysis. Shane serves on company and industry boards and is a frequent invited speaker, author and expert witness in analytical chemistry.
Shane holds a bachelor’s degree in chemistry from Washington State University and a PhD in
chemistry from the University of Rhode Island.
Co-Founder, Laboratory Director
Prior to co-founding Veloxity Labs, Mitch held senior bioanalytical and DMPK laboratory roles across the biotech and CRO industries. He has served as principal investigator for regulated and non-regulated preclinical studies and brings expertise in LC-MS/MS and HRMS method development, validation and sample analysis. His experience also includes in vitro assays such as microsomal stability and drug-drug interaction studies in human liver microsomes, as well as quantitative analysis of small molecules, metabolites, biomarkers and peptides across plasma, serum, whole blood and tissue matrices.
Mitch earned a bachelor’s degree in chemistry from Monmouth College and a PhD in analytical chemistry from the University of Missouri-Columbia.
Co-Founder, Associate Director
Colt began his scientific career in analytical testing before moving into bioanalysis at Alliance Pharma, where he progressed to a team lead role. His experience includes method validation, regulated sample analysis, toxicology studies and early-phase clinical work. He later brought that hands-on laboratory and operational experience to the founding of Veloxity Labs.
Colt received a bachelor’s degree in chemistry from Millersville University of Pennsylvania.
Co-Founder, Executive Vice President
Paul has led an esteemed 35-year career developing lease, finance and asset management products and strategies in the pharmaceutical, biotech, clinical, healthcare and related industries. He serves as President and CEO of McKinley Scientific after co-founding the company in 2000. McKinley enjoys client relationships in over 60 countries and a clientele that ranges from the very largest pharmaceutical companies in the world to newly formed and emerging laboratories.
Additionally, Paul serves as Managing Partner of Lake Mohawk Ventures (LMV), a long-term investment and management consulting firm that brings instrumentation management and financial services to the scientific industry. LMV also supported the formation and ongoing operations of Veloxity Labs.
Co-Founder, Vice President, Procurement
Martin brings 35 years of experience around high-technology equipment sourcing, sales, service and asset management after starting his career with IBM in 1980. Over the course of his career he served in various sales and leadership roles until he joined McKinley Scientific as senior vice president of sales at its inception in 1997. Additionally, he is a business partner at Lake Mohawk Ventures (LMV), a long-term investment and management consulting company that brings instrumentation management and financial services to the scientific industry. In his role with Veloxity Labs, his sourcing and acquisition skills are used to maintain required LCMS capacity. Originally from the UK, he now calls the US his country and home.
Martin earned a BA in Business Studies at the University of Hertfordshire in the UK.
Co-Founder, Vice President, Finance
Herb has been in the equipment finance industry for over 40 years. He currently serves as president of McKinley Capital, COO and executive vice president of McKinley Scientific and vice president of finance for Veloxity Labs. Previously, he served in a variety of leadership roles for Charter Financial, Inc. (Wells Fargo Equipment Finance) until he founded Commercial Finance Group, LLC in 2003. CFG merged with McKinley Scientific in 2016.
Herb has a bachelor’s degree in business and economics from Wagner College.
Director, Biochemistry and QA
Chris brings more than 25 years of experience as a drug discovery biochemist, with expertise in quality, regulatory bioanalysis, biomarkers and drug development. He has developed assays for the discovery and characterization of small molecules and macromolecules, contributing to patents, publications and clinical submissions. His laboratory experience includes immunoassays, LC-MS/MS, cell-based and PCR methods, as well as GCP-aligned drug-drug interaction work. Chris is a frequent speaker at SQA and other industry events.
Chris earned his PhD in Experimental Medicine and Biochemistry from the University of British Columbia and completed postdoctoral work at McGill University and the University of British Columbia.
Senior Director, BD
Callie brings more than 15 years of experience in the clinical research industry supporting pharmaceutical and medical device research and development for both human and animal health clients. During her career she has held various roles of increasing responsibility in marketing, commercial operations and sales. After earning her degree, she led the marketing activities for a large automotive dealership group. She then began her career in the CRO industry, first at Labcorp (Covance) where she supported bioanalytical, toxicology, pharmacology, drug metabolism and antibody generation services. From there she transitioned to Inotiv where she supported bioanalysis, pharmacology, toxicology and more.
Callie earned a bachelor’s degree in Business Management from North Central College.
Senior Director, BD
Shelly joined Veloxity Labs in May of 2023 where her extensive background in science and the drug development process helps her understand the challenges and needs of clients. She began her career in investigative toxicology at Eli Lilly before transitioning to Covance following their purchase of Eli Lilly’s toxicology campus, serving as a study director for non-regulated toxicology studies.
From there, she joined Seventh Wave Labs (Inotiv), serving in various business development roles and helping to shape the commercial engine as the company grew from 50 people to over 1000. She then moved to Prolytix in a business development role, supporting CMC process development and analytical services.
Shelly received her bachelor’s degree in Biology from Purdue University.
Senior Vice President
Ultragenyx
VP of Sales & Marketing
Shimadzu
Director, Bioanalytical Chemistry and DMPK
BioCryst Pharmaceuticals
Retired
Eli Lilly
President and CEO
Patel Kwan Consultancy
Vice President
Morton Community Bank
Founder
Shipley Pharma Insights
President of Discovery & Development
Insights, LLC
Bioanalytical Expert and Consultant
Drug Development Consultant
SVP of Product Development
BlueWater Bioscience
Planning a bioanalytical program? Connect with our scientists and business
development team to discuss your study, timeline and analytical needs.
